Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes

A. Lladó, P. Mannucci, A. F. Carpentier, S. Paris, Y. Blanco, A. Saiz, J. Y. Delattre, F. Graus

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The long-term evolution of Hu antibody (Hu-Ab) titers in patients with paraneoplastic neurologic syndromes (PNSs) is not known. Described is the evolution of Hu-Ab titers in 35 patients with PNS with a median follow-up of 32 months (range 6 to 108 months). No correlation was observed between Hu-Ab titers and neurologic outcome, tumor evolution, or type of treatment. Serial Hu-Ab determinations are not useful for monitoring the clinical outcome of patients with PNS.

Original languageEnglish
Pages (from-to)1947-1949
Number of pages3
JournalNeurology
Volume63
Issue number10
Publication statusPublished - Nov 23 2004

Fingerprint

Nervous System Paraneoplastic Syndromes
Antibodies
Nervous System Neoplasms

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lladó, A., Mannucci, P., Carpentier, A. F., Paris, S., Blanco, Y., Saiz, A., ... Graus, F. (2004). Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology, 63(10), 1947-1949.

Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. / Lladó, A.; Mannucci, P.; Carpentier, A. F.; Paris, S.; Blanco, Y.; Saiz, A.; Delattre, J. Y.; Graus, F.

In: Neurology, Vol. 63, No. 10, 23.11.2004, p. 1947-1949.

Research output: Contribution to journalArticle

Lladó, A, Mannucci, P, Carpentier, AF, Paris, S, Blanco, Y, Saiz, A, Delattre, JY & Graus, F 2004, 'Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes', Neurology, vol. 63, no. 10, pp. 1947-1949.
Lladó A, Mannucci P, Carpentier AF, Paris S, Blanco Y, Saiz A et al. Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. Neurology. 2004 Nov 23;63(10):1947-1949.
Lladó, A. ; Mannucci, P. ; Carpentier, A. F. ; Paris, S. ; Blanco, Y. ; Saiz, A. ; Delattre, J. Y. ; Graus, F. / Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes. In: Neurology. 2004 ; Vol. 63, No. 10. pp. 1947-1949.
@article{b45561e4444a41b586431133300d651e,
title = "Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes",
abstract = "The long-term evolution of Hu antibody (Hu-Ab) titers in patients with paraneoplastic neurologic syndromes (PNSs) is not known. Described is the evolution of Hu-Ab titers in 35 patients with PNS with a median follow-up of 32 months (range 6 to 108 months). No correlation was observed between Hu-Ab titers and neurologic outcome, tumor evolution, or type of treatment. Serial Hu-Ab determinations are not useful for monitoring the clinical outcome of patients with PNS.",
author = "A. Llad{\'o} and P. Mannucci and Carpentier, {A. F.} and S. Paris and Y. Blanco and A. Saiz and Delattre, {J. Y.} and F. Graus",
year = "2004",
month = "11",
day = "23",
language = "English",
volume = "63",
pages = "1947--1949",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes

AU - Lladó, A.

AU - Mannucci, P.

AU - Carpentier, A. F.

AU - Paris, S.

AU - Blanco, Y.

AU - Saiz, A.

AU - Delattre, J. Y.

AU - Graus, F.

PY - 2004/11/23

Y1 - 2004/11/23

N2 - The long-term evolution of Hu antibody (Hu-Ab) titers in patients with paraneoplastic neurologic syndromes (PNSs) is not known. Described is the evolution of Hu-Ab titers in 35 patients with PNS with a median follow-up of 32 months (range 6 to 108 months). No correlation was observed between Hu-Ab titers and neurologic outcome, tumor evolution, or type of treatment. Serial Hu-Ab determinations are not useful for monitoring the clinical outcome of patients with PNS.

AB - The long-term evolution of Hu antibody (Hu-Ab) titers in patients with paraneoplastic neurologic syndromes (PNSs) is not known. Described is the evolution of Hu-Ab titers in 35 patients with PNS with a median follow-up of 32 months (range 6 to 108 months). No correlation was observed between Hu-Ab titers and neurologic outcome, tumor evolution, or type of treatment. Serial Hu-Ab determinations are not useful for monitoring the clinical outcome of patients with PNS.

UR - http://www.scopus.com/inward/record.url?scp=8844240580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8844240580&partnerID=8YFLogxK

M3 - Article

C2 - 15557520

AN - SCOPUS:8844240580

VL - 63

SP - 1947

EP - 1949

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -